Posts tagged ‘Pipeline’
Mice seem to get bad PR; there’s far more people that like cats……..So in the interests of fair balance, we’d like to draw attention to the increasing importance of preclinical mouse models in cancer drug development.
Pieter Droppert on Biotech Strategy Blog discusses how innovations in translational medicine, and improved mouse models of human cancer are having a major impact on bringing new cancer drugs to market.
So, time for some good thoughts about mice (with apologies to cat lovers out there).
Groundbreaking research on identification of ZNF703 oncogene in breast cancer
February 21st, 2011
Daedalus
Sally Church on the Pharma Strategy Blog analyzes the significance of new research that has identified a new oncogene associated with 1 in 12 breast cancers.
Research published by Holland et al, in the journal, EMBO Molecular Medicine, has identified the ZNF703 oncogene to be linked with Luminal B breast cancer.
This is the first oncogene to be discovered in 5 years since HER2, and has tremendous potential as a target for drug development.
As Sally comments on her blog “it’s much easier to design a drug or therapeutic once you have a valid target to aim for and with more specific targeting, comes improved patient outcomes.”
This is important news and Sally’s blog post has more in-depth insight and analysis.
Following on from news about the emerging competitive landscape in osteoporosis, Pieter Droppert on the Biotech Strategy Blog considers in more detail Merck’s odanacatib, currently in phase III clinical trials.
Odanacatib is first of a new class of drugs for the treatment of osteoporosis known as cathepsin K inhibitors (CAT-K). You can read more on Biotech Strategy Blog about this new product, its mechanism of action and the marketing strategy associated with its development.
While at Quintiles, Pieter Droppert was a lead CRA and European project manager for risedronate clinical trials, and he has since maintained an interest in osteoporosis new product development.
On the Biotech Strategy Blog, he discusses a recent review published in Nature Reviews Drug Discovery on the emerging treatments in development for osteoporosis. He comments on some of the barriers to market entry that companies will increasingly face such as pressure not to do placebo-controlled trials with high fracture-risk subjects.
For further commentary and insight on the osteoporosis market, read the full post on Biotech Strategy Blog.
Adding the new Google Custom Search feature to Sally Church’s Pharma Strategy Blog allows readers to delve into 800 posts for insight and analysis on oncology, hematology, targeted therapies, pathways, new products, marketing strategy, science, clinical research, translational medicine, social media and much more.
Check the new Google powered search feature on Pharma Strategy Blog
Sanofi's iniparib misses primary endpoints in newly diagnosed triple negative breast cancer
January 28th, 2011
Daedalus
Published by Sally Church on Pharma Strategy Blog
BREAKING NEWS
Sanofi-aventis have just announced :
“A randomized Phase III trial evaluating BSI-201 (iniparib*) in patients with metastatic triple-negative breast cancer (mTNBC) did not meet the pre-specified criteria for significance for co-primary endpoints of overall survival and progression-free survival.”
Iniparib was thought to offer the best chance of success with PARP inhibitors because the others have so far been shown to be
- more potent
- more challenging to combine given the toxicities involved.
Clearly it is a fine line between potency and toxicities with this particular class.
Click here to read the full post on Pharma Strategy Blog
Published by Sally Church on Pharma Strategy Blog
Since the human genome was sequenced in 2000, much progress has been made with cancer research. In a review article published this week in the New England Journal of Medicine, McDermott et al., (2011), provide insight on what has taken place and what the future may hold.
Click here to read the full post on Pharma Strategy Blog
Published by Sally Church on Pharma Strategy Blog
Published by Sally Church on Pharma Strategy Blog